NeuroSense to Present New Data on PrimeC for ALS at AD/PD 2026 Conference
ByAinvest
Wednesday, Mar 18, 2026 11:43 am ET1min read
NRSN--
NeuroSense Therapeutics will present new data on PrimeC, a therapy for amyotrophic lateral sclerosis (ALS), at the AD/PD 2026 conference. Dr. Christian Lunetta will present findings from the Phase 2b PARADIGM trial and insights into disease mechanisms and treatment effects. The data will inform the design of the global Phase 3 PARAGON trial, currently in development. The presentation will review key clinical and biomarker findings from the PARADIGM trial and provide an important scientific foundation for advancing therapeutic development in ALS.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet